T. Breen

1.4k total citations
29 papers, 1.0k citations indexed

About

T. Breen is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, T. Breen has authored 29 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 7 papers in Surgery. Recurrent topics in T. Breen's work include Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Research Studies (8 papers) and Lung Cancer Diagnosis and Treatment (4 papers). T. Breen is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Research Studies (8 papers) and Lung Cancer Diagnosis and Treatment (4 papers). T. Breen collaborates with scholars based in United States and Canada. T. Breen's co-authors include Beth E. Juliar, Marcia L. Shew, J. Dennis Fortenberry, Brahim Qadadri, Wanzhu Tu, Darron R. Brown, Nasser H. Hanna, Paul Y. Kwo, J. DeLuca and M. Henderson and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Brain Research.

In The Last Decade

T. Breen

28 papers receiving 979 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
T. Breen United States 10 401 298 286 240 227 29 1.0k
João Subtil Spain 15 101 0.3× 332 1.1× 623 2.2× 435 1.8× 134 0.6× 61 1.1k
Yeon-Joo Kim South Korea 15 164 0.4× 166 0.6× 191 0.7× 353 1.5× 130 0.6× 39 739
A. Chan Canada 4 338 0.8× 44 0.1× 54 0.2× 369 1.5× 79 0.3× 5 777
Wen-Yen Huang Taiwan 11 131 0.3× 140 0.5× 94 0.3× 110 0.5× 258 1.1× 16 485
Stephen Harrow United Kingdom 16 153 0.4× 144 0.5× 343 1.2× 434 1.8× 46 0.2× 40 960
Andrea Salmi Italy 10 582 1.5× 218 0.7× 92 0.3× 127 0.5× 834 3.7× 31 1.1k
William P. Irvin United States 17 225 0.6× 227 0.8× 280 1.0× 82 0.3× 10 0.0× 26 821
R. Bonnet Germany 15 86 0.2× 57 0.2× 289 1.0× 500 2.1× 29 0.1× 28 813
Feng-Yan Li China 17 150 0.4× 286 1.0× 268 0.9× 250 1.0× 9 0.0× 40 740
Janis P. O’Malley United States 9 78 0.2× 60 0.2× 145 0.5× 155 0.6× 23 0.1× 23 553

Countries citing papers authored by T. Breen

Since Specialization
Citations

This map shows the geographic impact of T. Breen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Breen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Breen more than expected).

Fields of papers citing papers by T. Breen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Breen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Breen. The network helps show where T. Breen may publish in the future.

Co-authorship network of co-authors of T. Breen

This figure shows the co-authorship network connecting the top 25 collaborators of T. Breen. A scholar is included among the top collaborators of T. Breen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Breen. T. Breen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hoimes, Christopher, Costantine Albany, Jean Hoffman‐Censits, et al.. (2018). A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC). Annals of Oncology. 29. viii726–viii726. 26 indexed citations
3.
Chiorean, E. Gabriela, Joel Picus, T. Breen, et al.. (2015). Phase I/II study of everolimus (E) with irinotecan (Iri) and cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC): Hoosier Cancer Research Network GI05-102.. Journal of Clinical Oncology. 33(15_suppl). 3618–3618. 4 indexed citations
6.
7.
Fang, Fang, Curt Balch, Jeanne M. Schilder, et al.. (2010). A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum‐resistant, epithelial ovarian cancer. Cancer. 116(17). 4043–4053. 139 indexed citations
8.
Cárdenes, Higinia R., T R Price, Susan M. Perkins, et al.. (2010). Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clinical & Translational Oncology. 12(3). 218–225. 233 indexed citations
9.
Cárdenes, Higinia R., T R Price, Susan M. Perkins, et al.. (2008). Phase I Trial of Stereotactic Body Radiation Therapy for Primary Hepatocellular Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 72(1). S128–S129. 5 indexed citations
10.
Jalal, Shadia I., David Waterhouse, Martin J. Edelman, et al.. (2007). Pemetrexed plus cetuximab in patients (pts) with recurrent non-small cell lung cancer (NSCLC): A phase I-IIa dose-ranging study from the Hoosier Oncology Group. Journal of Clinical Oncology. 25(18_suppl). 7698–7698. 11 indexed citations
11.
Shen, Changyu, T. Breen, Lacey E. Dobrolecki, et al.. (2007). Comparison of computational algorithms for the classification of liver cancer using SELDI mass spectrometry: a case study.. PubMed. 3. 329–39. 2 indexed citations
12.
Ademuyiwa, Foluso O., Cynthia S. Johnson, Angela White, et al.. (2007). Prognostic Factors in Stage III Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 8(8). 478–482. 47 indexed citations
13.
Shen, Changyu, T. Breen, Lacey E. Dobrolecki, et al.. (2007). Comparison of Computational Algorithms for the Classification of Liver Cancer using SELDI Mass Spectrometry: A Case Study. Cancer Informatics. 3. 2816855308–2816855308. 3 indexed citations
14.
Henderson, M., et al.. (2007). Preliminary Toxicity Analysis of a Phase I/II Trial Evaluating Stereotactic Body Radiotherapy for the Treatment of Hepatocellular Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 69(3). S297–S297. 2 indexed citations
15.
Einhorn, Lawrence H., Ramaswamy Govindan, John A. Axelson, et al.. (2006). Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: A Hoosier Oncology Group phase II trial. Lung Cancer. 52(1). 93–97. 75 indexed citations
16.
Hanna, Nasser H., Rafat Ansari, Sumeet Bhatia, et al.. (2006). Pemetrexed in patients (pts) with relapsed small cell lung cancer (SCLC): A phase II study from the Hoosier Oncology Group. Journal of Clinical Oncology. 24(18_suppl). 7063–7063. 12 indexed citations
17.
Brown, Darron R., Marcia L. Shew, Brahim Qadadri, et al.. (2004). A Longitudinal Study of Genital Human Papillomavirus Infection in a Cohort of Closely Followed Adolescent Women. The Journal of Infectious Diseases. 191(2). 182–192. 315 indexed citations
18.
Muir, Holly A., et al.. (2000). A Multi Center Study of the Effects of Analgesia on the Progress Of Labor . Anesthesiology. 2000(4). NA–NA. 3 indexed citations
19.
Breen, T. & Sandra L. Morzorati. (1996). Innate differences in medial septal area burst firing neurons and the hippocampal theta rhythm during ambulation in selectively bred rat lines. Brain Research. 714(1-2). 156–164. 9 indexed citations
20.
Morzorati, Sandra L., T. Breen, Lawrence Lumeng, & T.-K. Li. (1994). Comparison of innate EEG parameters in rat lines selected for ethanol preference. Alcohol. 11(3). 253–258. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026